DNAPrint & Emory:

http://newsblaze.com/story/2006081704000800001.mwir/newsblaze/MARKWIRE/Marketwire-Releases.html

Ann

Trace Genetics Partner's page:

http://www.tracegenetics.com/partners.html

Ann

All right, Brian...

Have a good one,
Ann

Sorry - this posting does not include the audio tour on biometrics.

Copied, but, did not work out.

Later,
Ann

Biometric Symposium:

http://dnaprint.biometrics.e-symposium.com/

Ann

brian:
"Sound's like a "Winner"!

Don't know what you're referring to, but,thank you.

Take care,
Ann

I know, it's 06 - but, interesting to review for current edification.

Ann

Police One - "The Real Value of DNA Witness:"

http://www.policeone.com/police-products/investigation/DNA-forensics/press-releases/1157882/

Ann

Interesting - T. Frudakis on this page:

http://www.benlaguer.com/links.html

Ann

Cloud:

I'm entitled, aren't I? - lol

Ann

"We are genuinely pleased to reach this agreement with Dutchess, which could settle its DNAPrint® Genomics debt in full with the planned spin-off of the DNAPrint® Pharmaceuticals division and help to ensure the stability of the parent Company's finances," stated President and Chief Executive Officer Richard Gabriel.

"Spin-off" rings magic w/my ears...after all these many years of waiting and anticipating for something to substantially take such a positive turn!" Good-by R/S - hello S/O...bring it on!!

Ann

I realize it's '05 and probably dated...no need to reply, Sandoz - it's better than posting nothing on DNAP at this point in time - so what - haven't ever seen you post anything expect off-comments - let's see you come up with retrievals of some articles or events and posting up-to-date news on this board - lol

Ann

While waiting for some possible big news or PR...you might want to listen to this audio presentation...we're all just waiting and for Big Time! - lol...

Ann

DBAP appears in upper right hand corner of this audio symposium presentation:

http://e-symposium.brighttalk.com/brightcast/invitation

Ann

Thanks, DMcng

Ann

Sandoz:
"Good ol'Ann, dredging up REALLY OLD NEWS, as usual."

Good ol'Sandoz, reading REALLY OLD NEWS, as usual.

Adios,
Ann

"Press Release Source: DNAPrint Genomics, Inc.

DNAPrint Genomics Receives Patent for Identifying Links Between Gene Sequences and Medical Traits
Tuesday September 19, 2006 7:00 am ET

SARASOTA, FL--(MARKET WIRE)--Sep 19, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News) today announced that the Company has formally been granted a patent by the U.S. Patent and Trademark Office for Methods for the Identification of Genetic Features for Complex Genetics Classifiers. The patent protects the Company's methods for identifying links between gene sequences and phenotypes (physical or medical traits), and follows a Notice of Allowance for the process in April of this year.

"It is important to protect the company's technologies and the revenue that can be derived from them," stated DNAPrint Genomics Founder and Chief Scientific Officer Tony N. Frudakis. "Our proprietary methods for marking gene sequences are especially important, because they are the key to developing theranostic drugs."

The patent provides legal protection for DNAPrint's status as one of few companies currently capable of performing objective, assumption-free haplotype analysis of DNA strands.

DNAPrint Genomics currently holds two other patents and has several others pending or in the hands of patent counsel.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Ann

Don't remember reading this grant of patent for DNAP release:

http://sidesearch.lycos.com/?query=dnaprint&first=1&hurl=http%3A%2F%2Fwww%2Efamilytreedna%2E...

Ann

You can scroll & read the entire context, if you wish!

Ann

Part 3: DNAP mentioned:

http://www.bio-itworld.com/archive/090902/pharma.html?page=3

Ann

(Part 2):

http://www.bio-itworld.com/archive/090902/pharma.html?page=2

Ann

The New Pharmagenomics - DNAP mentioned - Part I:

http://www.bio-itworld.com/archive/090902/pharma.html?page=1

Ann

Cloud:

Not a problem, either way.

Take care,
Ann

Cloud:

I agree with your comments and wouldn't mind your letter going to DNAP. It really says it all. - But, it's MHO

Take care,
Ann

Chris:

Over & out!

Take care,
Ann

Hey, Chris...

Ann

Guess I was a little critical, Chris. A lot of us have been "vegitating" here a long time! When will we finally breakout? Sooner looks better than later.

Take care,
Ann

Chris:
"I feel letting DNAG no we do not feel communication is up to snuff"

I hope your request does not contain any negativism towards DNAG, but that your context will be tactful. I feel it's necessary to point this out to you, Chris, since, in a sense, you will be representing me.

Take care,
Ann

Up-to-date Hoovers on DNAP:

http://www.hoovers.com/dnaprint-genomics/--ID__107230--/free-co-factsheet.xhtml

Ann

Sorry, for the dissertations - all good, though! - Can put me on block or skip my posts...this is the "Seven Year's Itch?" - lol

Ann

Interesting posts, while we are awaiting or anticipating more news...!

Ann

More:

http://e-symposium.brighttalk.com/brightcast/invitation

Ann

Interesting:

Flashback:

http://dnaprint.biometrics.e-symposium.com/

Ann

dnawitness.net:

http://www.dnawitness.net/

Ann

10/12/2006

DNAPrint Genomics To Exhibit Enhanced

SARASOTA, Fla. – DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that the Company will exhibit its products, including DNAWitness™ with Retinome™ 2.0, at the 113th Annual International Association of Chiefs of Police (IACP) Conference in Booth 803 at the Boston Exhibition and Convention Center in Boston, Mass., from Sunday, Oct. 15 through Tuesday, Oct. 17.

“We are extremely pleased to be exhibiting DNAWitness™ and other products at the IACP Conference, which draws 14,000 law enforcement officials from all over the world,” stated DNAPrint President and Chief Executive Officer Richard Gabriel. “We look forward to demonstrating how DNAWitness™ can improve their crime scene investigations and enhance their forensic capabilties.”

DNAWitness™ employs patent-pending, database-driven methods to infer elements of physical appearance from crime scene DNA and allow forensic investigators to “paint” molecular portraits of a suspect. This innovative forensic technology has already been used in some 130 cases, including the arrest and conviction of Derrick Todd Lee for a series of murders in Louisiana and in New Scotland Yard’s search for the so-called Minstead Rapist, a serial sex offender who is operating in an area south of London.

DNAWitness™ derives the percentage of European, East Asian, Native American, and Sub- Saharan African markers in a person’s DNA. This ratio for an individual is termed Bio- Geographical Ancestry (BGA), representing general characteristics that can be matched with a searchable database containing information and photographs collected from samples around the world, leading to more accurate identifications of potential of criminalsuspects.

Retinome™ 2.0 can be combined with the DNAWitness™ product to determine a person’s eye color. The Company’s patent-pending technology identifies additional markers covering newly identified and informative regions of the human pigmentation gene OCA2. The Company has also developed a Retinome 2.0 capillary electrophoresis kit, which permits investigators to test Retinome 2.0 in their own laboratories, obviating the need to ship their samples to DNAPrint (though that option is still available).

DNAPrint will also be exhibiting its tests for mitochondrial and Y DNA trace samples or mixtures.

For more information, visit www.dnawitness.net.

Ann

Forensic Services offered at Trace Genetics:

http://www.tracegenetics.com/services_forensics.html

Ann

In retrospect:

Tony Frudakis was involved with issuance of this patent in '05 while working for Corixa:

http://www.pharmcast.com/Patents100/Yr2005/Mar2005/030105/6861506_Breast030105.htm

Ann

Bri:

In my viewpoint, probably the best glimmer of hope as of yet!

Take care,
Ann

Johnnyfiber, can I quote you?

"Posted by: johnnyfiber
In reply to: A deleted message Date:3/15/2007 4:26:26 PM
Post #of 67513

I sent a request and received an e-mail from Designed Marketing. There were 2 pdf attachments. copy:

DNAPrint™ Genomics, Inc. (“DNAPrint”) develops and markets genetic testing products and services. The company’s scientists aim their research towards discovery of DNA analysis solutions to serve clients in Forensic Science, Genealogical Research, and Pharmaceutical development. DNAPrint™ Genomics, Inc. is a cutting edge company with innovative products and solutions that could make a profound impact on improving our health care and combating crime and terrorism around the world.
Improving health care: DNAPrint has a breakthrough product
that allows the patient to be tested prior to beginning the drug
treatment to determine whether that drug treatment will be effective for them based on their specific DNA. This company’s
breakthrough products could make the difference in life or
death in patient. Over 100,000 people die each year from
improper drug treatment. Imagine the demand for this company’s
products when physicians and patients demand DNAPrint’s
products as the new standard practice to optimize the
diagnosis and treatment of their illness. Combating crime and terrorism: Based on a single piece of DNA, DNAPrint can provide law enforcement detailed descriptions and drawings of the suspect. Their products provide “exclusion” capabilities for investigators, and can narrow a list of suspects from thousands down to just a few.
Why Invest Now:
• Hunting for the right drug therapy; revolutionized by DNAPrint!
• Hunting for a serial killer; revolutionized by DNAPrint!
• Hundreds of billions of dollars spent on healthcare, and demand
for new services and products is skyrocketing. World-wide
spending for new tools in the fight against terrorism and crime is skyrocketing.
• Company’s current market value around $4 million, and
Analyst recently estimated this company’s market value at
over $30 million. A potential 700-800% jump in value!!!
As demand for a company’s products skyrocket, typically their sales and stock price also skyrocket. This is your chance to get in early stage just before the potential surge in demand, and The Street realizes the potential of this up and coming company.

Ann

Dmceng:

Thank you for your comments to me!

Take care,
Ann